Literature DB >> 34107286

Structural analysis of the full-length human LRRK2.

Alexander Myasnikov1, Hanwen Zhu2, Patricia Hixson2, Boer Xie3, Kaiwen Yu4, Aaron Pitre5, Junmin Peng6, Ji Sun7.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are commonly implicated in the pathogenesis of both familial and sporadic Parkinson's disease (PD). LRRK2 regulates critical cellular processes at membranous organelles and forms microtubule-based pathogenic filaments, yet the molecular basis underlying these biological roles of LRRK2 remains largely enigmatic. Here, we determined high-resolution structures of full-length human LRRK2, revealing its architecture and key interdomain scaffolding elements for rationalizing disease-causing mutations. The kinase domain of LRRK2 is captured in an inactive state, a conformation also adopted by the most common PD-associated mutation, LRRK2G2019S. This conformation serves as a framework for structure-guided design of conformational specific inhibitors. We further determined the structure of COR-mediated LRRK2 dimers and found that single-point mutations at the dimer interface abolished pathogenic filamentation in cells. Overall, our study provides mechanistic insights into physiological and pathological roles of LRRK2 and establishes a structural template for future therapeutic intervention in PD.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LRRK2; LRRK2 dimer; LRRK2 mutations; Parkinson's disease; kinase

Mesh:

Substances:

Year:  2021        PMID: 34107286      PMCID: PMC8887629          DOI: 10.1016/j.cell.2021.05.004

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  69 in total

1.  Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.

Authors:  Elena Purlyte; Herschel S Dhekne; Adil R Sarhan; Rachel Gomez; Pawel Lis; Melanie Wightman; Terina N Martinez; Francesca Tonelli; Suzanne R Pfeffer; Dario R Alessi
Journal:  EMBO J       Date:  2019-01-15       Impact factor: 11.598

2.  Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.

Authors:  Bernd K Gilsbach; Franz Y Ho; Ingrid R Vetter; Peter J M van Haastert; Alfred Wittinghofer; Arjan Kortholt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

3.  LRRK2 Parkinson disease mutations enhance its microtubule association.

Authors:  Lauren R Kett; Daniela Boassa; Cherry Cheng-Ying Ho; Hardy J Rideout; Junru Hu; Masako Terada; Mark Ellisman; William T Dauer
Journal:  Hum Mol Genet       Date:  2011-11-11       Impact factor: 6.150

Review 4.  The guanine nucleotide-binding switch in three dimensions.

Authors:  I R Vetter; A Wittinghofer
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

Review 5.  Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.

Authors:  Byoung Dae Lee; Valina L Dawson; Ted M Dawson
Journal:  Trends Pharmacol Sci       Date:  2012-05-09       Impact factor: 14.819

6.  LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner via its armadillo domain.

Authors:  Emma McGrath; Dieter Waschbüsch; Brian M Baker; Amir R Khan
Journal:  Small GTPases       Date:  2019-09-25

7.  Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis.

Authors:  Martin Steger; Federico Diez; Herschel S Dhekne; Pawel Lis; Raja S Nirujogi; Ozge Karayel; Francesca Tonelli; Terina N Martinez; Esben Lorentzen; Suzanne R Pfeffer; Dario R Alessi; Matthias Mann
Journal:  Elife       Date:  2017-11-10       Impact factor: 8.140

8.  The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.

Authors:  Sven H Schmidt; Matthias J Knape; Daniela Boassa; Natascha Mumdey; Alexandr P Kornev; Mark H Ellisman; Susan S Taylor; Friedrich W Herberg
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-10       Impact factor: 11.205

Review 9.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

10.  Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.

Authors:  Elena Purlyte; Herschel S Dhekne; Adil R Sarhan; Rachel Gomez; Pawel Lis; Melanie Wightman; Terina N Martinez; Francesca Tonelli; Suzanne R Pfeffer; Dario R Alessi
Journal:  EMBO J       Date:  2017-12-06       Impact factor: 11.598

View more
  22 in total

Review 1.  LRRK2 and idiopathic Parkinson's disease.

Authors:  Emily M Rocha; Matthew T Keeney; Roberto Di Maio; Briana R De Miranda; J Timothy Greenamyre
Journal:  Trends Neurosci       Date:  2022-01-04       Impact factor: 13.837

Review 2.  LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights.

Authors:  Patrick D Skelton; Valerie Tokars; Loukia Parisiadou
Journal:  Cells       Date:  2022-01-05       Impact factor: 7.666

3.  Impact of Type II LRRK2 inhibitors on signaling and mitophagy.

Authors:  Anna Tasegian; Francois Singh; Ian G Ganley; Alastair D Reith; Dario R Alessi
Journal:  Biochem J       Date:  2021-10-15       Impact factor: 3.857

4.  LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains.

Authors:  Jui-Hung Weng; Phillip C Aoto; Robin Lorenz; Jian Wu; Sven H Schmidt; Jascha T Manschwetus; Pallavi Kaila-Sharma; Steve Silletti; Sebastian Mathea; Deep Chatterjee; Stefan Knapp; Friedrich W Herberg; Susan S Taylor
Journal:  PLoS Biol       Date:  2022-02-22       Impact factor: 8.029

Review 5.  LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.

Authors:  Eunice Eun Seo Chang; Philip Wing-Lok Ho; Hui-Fang Liu; Shirley Yin-Yu Pang; Chi-Ting Leung; Yasine Malki; Zoe Yuen-Kiu Choi; David Boyer Ramsden; Shu-Leong Ho
Journal:  Transl Neurodegener       Date:  2022-02-14       Impact factor: 8.014

6.  Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.

Authors:  Ranjan K Singh; Ahmed Soliman; Giambattista Guaitoli; Eliza Störmer; Felix von Zweydorf; Thomas Dal Maso; Asmaa Oun; Laura Van Rillaer; Sven H Schmidt; Deep Chatterjee; Joshua A David; Els Pardon; Thomas U Schwartz; Stefan Knapp; Eileen J Kennedy; Jan Steyaert; Friedrich W Herberg; Arjan Kortholt; Christian Johannes Gloeckner; Wim Versées
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 11.205

7.  The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.

Authors:  Molly FitzGibbon; Elizabeth M Earley; Hannah Ahrendt; Adrienne E D Stormo; Farbod Shavarebi; Lotus S Lum; Erik Verschueren; Danielle L Swaney; Gaia Skibinski; Abinaya Ravisankar; Jeffrey van Haren; Emily J Davis; Jeffrey R Johnson; John Von Dollen; Carson Balen; Jacob Porath; Claudia Crosio; Christian Mirescu; Ciro Iaccarino; William T Dauer; R Jeremy Nichols; Torsten Wittmann; Timothy C Cox; Steve Finkbeiner; Nevan J Krogan; Scott A Oakes; Annie Hiniker
Journal:  J Cell Biol       Date:  2022-03-10       Impact factor: 10.539

8.  Molecular basis of crosstalk in nuclear receptors: heterodimerization between PXR and CAR and the implication in gene regulation.

Authors:  Monicah N Bwayi; Efren Garcia-Maldonado; Sergio C Chai; Boer Xie; Shirish Chodankar; Andrew D Huber; Jing Wu; Kavya Annu; William C Wright; Hyeong-Min Lee; Jayaraman Seetharaman; Jingheng Wang; Cameron D Buchman; Junmin Peng; Taosheng Chen
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

9.  Editorial: LRRK2-Fifteen Years From Cloning to the Clinic.

Authors:  Hardy Rideout; Elisa Greggio; Arjan Kortholt; R Jeremy Nichols
Journal:  Front Neurosci       Date:  2022-04-11       Impact factor: 4.677

10.  A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively.

Authors:  Antoine Marchand; Alessia Sarchione; Panagiotis S Athanasopoulos; Hélène Bauderlique-Le Roy; Liesel Goveas; Romain Magnez; Matthieu Drouyer; Marco Emanuele; Franz Y Ho; Maxime Liberelle; Patricia Melnyk; Nicolas Lebègue; Xavier Thuru; R Jeremy Nichols; Elisa Greggio; Arjan Kortholt; Thierry Galli; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2022-03-17       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.